ArticleCureus2026
Beyond Actionability: A Real-World Audit and Quality Improvement Initiative to Refine Shared Decision-Making Following 50-Gene Next-Generation Sequencing Results in Non-small Cell Lung Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBroad-panel next-generation sequencing (NGS) improves detection of clinically relevant genomic alterations beyond those detected by conventional targeted panels in advanced non-small cell lung cancer (NSCLC). However, the influence of these additional findings on shared decision-making (SDM) in routine clinical practice remains poorly described. This study evaluated the incremental value of an institutional 50-gene NGS panel in documenting SDM and characterized the genomic landscape in advanced NSCLC. MATERIALS AND
methodsThis retrospective observational study included consecutive patients with biopsy-proven advanced NSCLC who underwent in-house 50-gene NGS between June 2025 and June 2026 and had at least one documented post-NGS oncology consultation. Formalin-fixed paraffin-embedded tumor samples with ≥20% tumor cellularity were analyzed using an in-house 50-gene panel. Genomic alterations across all 50 genes were analyzed to characterize the molecular landscape, and alterations in the 37 genes exclusive to the expanded panel were evaluated for their impact on SDM. SDM was assessed across six predefined domains: targeted therapy discussion, molecular tumor board (MTB) referral, departmental discussion, clinical trial discussion, prognostic counseling, and genetic clinic referral.
resultsA total of 113 patients were included (median age, 64.5 years; 74.3% males). The most frequent alterations in the 50-gene panel were TP53 (45.1%), KRAS (25.7%), EGFR (20.4%), CDKN2A (16.8%), FGFR3 (9.7%), and FGFR1 (7.1%). Additional genomic alterations exclusive to the expanded panel were identified in 49 patients (43.4%). However, only 16 patients (32.7%) had documented SDM influenced by these additional findings. Departmental discussion was the most frequently documented SDM domain (24.5%), whereas MTB referral (4.1%), targeted therapy discussion (4.1%), and clinical trial discussion (6.1%) were infrequent. No documented prognostic counseling or genetic referral was identified. A structured post-NGS SDM documentation template was developed.
conclusionsGenomic profiling using a 50-gene NGS panel identified additional genomic alterations in patients with advanced NSCLC; however, documentation of the influence of these findings on SDM remained limited. Implementation of a standardized post-NGS documentation template may improve SDM documentation and facilitate more comprehensive integration of genomic findings into routine precision oncology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.